Botox injections into the joint for painful thumb base osteoarthritis
Tests onabotulinumtoxinA joint injections for pain in adults with thumb base osteoarthritis.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- Bordeaux, Montpellier Cedex 5, and Paris, FranceSee the 3 sites
- Trial code
- Registry title
- RHIBOT II - Medium- and long-term efficacy of two ultrasound-guided intra-articular injections of onabotulinumtoxinA (Botox®) combined with custom-made rigid splinting in painful base-of-thumb osteoarthritis : a randomized double-blind controlled trial in three-parallel arms
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 120 people, planned
- Started
- 3 Dec 2025
- Expected to end
- 2 Dec 2027
- Type of study
- Interventional
- Record updated
- 25 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with painful osteoarthritis (joint wear) at the base of the thumb. It compares Botox injections into the joint with salt-water injections, together with a custom-made rigid splint.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Pain at the base of the thumb of at least 30 on a 0 to 100 scale. X-ray shows wear of the thumb base joint (trapezometacarpal joint) with at least two signs: bone spurs, joint space narrowing, hardening of the bone under the cartilage, or small cysts in that bone. The 1990 ACR criteria for hand osteoarthritis, adapted to this joint, must be met.
- Earlier treatment
- No corticosteroids by muscle, vein or mouth for up to 2 months before. No treatments injected into the joint for up to 2 months before. No past thumb surgery.
- Biomarker or test result
- Women who could become pregnant need a negative pregnancy test.
Main reasons for not taking part
- Osteoarthritis caused by another condition, or wear mainly at the scaphotrapezial joint on x-ray
- Inflammatory or crystal-related rheumatic disease, epilepsy, or nerve disorders of the hands other than carpal tunnel syndrome
- Pregnancy, breastfeeding, or no birth control in women who could become pregnant
- Hand or wrist injury in up to the last 2 months
- Cannot have onabotulinumtoxinA, or unable to speak and read French
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Individuals aged at least 18 years
- Pain intensity of at least 30 on a self-administered 11-point pain numeric rating scale (0: no pain to 100: maximal pain)
- Pain involving the base of the thumb
- X-ray evidence of trapezometacarpial osteoarthritis with at least two of the following items involving the trapezometacarpial joint: osteophytes, joint space narrowing, subchondral bone sclerosis, or subchondral cysts
- 1990 ACR classification criteria for hand osteoarthritis adapted to trapezometacarpial osteoarthritis
- Affiliation with a mode of social security (profit or being entitled)
- Negative pregnancy test in women of childbearing potential
Who cannot take part
- Use of IM, IV or oral corticosteroids for up to 2 months
- History of thumb surgery, inflammatory or crystal-associated rheumatic disease, or epilepsy
- Neurological disorders involving the hands other than carpal tunnel syndrome
- Collagen disorders involving the hands
- Secondary osteoarthritis
- Protected adults (including individual under guardianship by court order)
- Pregnant women and lactation; lack of contraception for women of childbearing potential
- Patient participating in another investigational therapeutic study
- Patient unable to speak and read French
- Contra-indication to onabotulinumtoxinA
- Osteoarthritis predominating at the scaphotrapezial joint on x-ray
- Bilateral trapezometacarpial osteoarthritis without a predominant painful side
- Hand or wrist trauma for up to 2 months
- Intra-articular treatments for up to 2 months
This trial is currently available in France.
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
About the trial
What the trial wants to find out
Our main objective will be to compare the effects of 2 intra-articular injections of onabotulinumtoxinA with those of 1 intra-articular injection of onabotulinumtoxinA and 1 of normal saline and those of 2 intra-articular injections of normal saline on base-of-thumb pain at 6 months after the first injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- RHIBOT II - Medium- and long-term efficacy of two ultrasound-guided intra-articular injections of onabotulinumtoxinA (Botox®) combined with custom-made rigid splinting in painful base-of-thumb osteoarthritis : a randomized double-blind controlled trial in three-parallel arms
- Plain-language title
- Botox injections into the joint for painful thumb base osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 November 2025